Surrozen (NASDAQ:SRZN) COO Charles Williams Sells 2,036 Shares

Key Points

• COO Charles Williams sold 2,036 shares on May 4 at an average price of $33.33 for total proceeds of $67,859.88, leaving him with 16,571 shares (a 10.94% reduction in his stake).
• Surrozen delivered a large earnings miss for the quarter (EPS -$7.59 vs. consensus -$1.29) with revenue of $0.53M and extremely negative profitability metrics (ROE -4,055.04%, net margin -7,476.67%).
• The stock trades around $32.64 with a market cap of about $375M, and analysts hold a consensus "Moderate Buy" rating with an average price target of $38 amid mixed buy/hold/sell coverage.

Surrozen, Inc. (NASDAQ:SRZN - Get Free Report) COO Charles Williams sold 2,036 shares of the firm's stock in a transaction on Monday, May 4th. The stock was sold at an average price of $33.33, for a total value of $67,859.88. Following the transaction, the chief operating officer directly owned 16,571 shares of the company's stock, valued at $552,311.43. The trade was a 10.94% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Surrozen Price Performance

Surrozen stock traded up $0.57 during mid-day trading on Tuesday, hitting $32.64. 95,295 shares of the company were exchanged, compared to its average volume of 113,375. The business's 50 day simple moving average is $28.15 and its two-hundred day simple moving average is $21.98. The company has a market capitalization of $375.03 million, a P/E ratio of -0.98 and a beta of 0.59. Surrozen, Inc. has a 12-month low of $5.90 and a 12-month high of $35.00.

Surrozen (NASDAQ:SRZN - Get Free Report) last released its quarterly earnings results on Monday, March 23rd. The company reported ($7.59) earnings per share for the quarter, missing the consensus estimate of ($1.29) by ($6.30). The company had revenue of $0.53 million for the quarter, compared to analysts' expectations of $0.66 million. Surrozen had a negative return on equity of 4,055.04% and a negative net margin of 7,476.67%. Equities research analysts predict that Surrozen, Inc. will post -4.04 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the company. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $40.00 price objective on shares of Surrozen in a research report on Tuesday, March 24th. HC Wainwright reaffirmed a "buy" rating and issued a $36.00 price objective (up from $32.00) on shares of Surrozen in a research report on Tuesday, March 24th. TD Cowen assumed coverage on Surrozen in a research report on Tuesday, April 21st. They issued a "buy" rating for the company. Wall Street Zen raised Surrozen from a "sell" rating to a "hold" rating in a research report on Saturday, March 28th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Surrozen in a research report on Tuesday, April 21st. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Surrozen currently has a consensus rating of "Moderate Buy" and an average price target of $38.00.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. boosted its holdings in Surrozen by 50.0% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 1,500 shares of the company's stock valued at $34,000 after acquiring an additional 500 shares during the last quarter. Persistent Asset Partners Ltd acquired a new position in shares of Surrozen during the fourth quarter worth about $99,000. Citadel Advisors LLC lifted its stake in shares of Surrozen by 32.8% during the third quarter. Citadel Advisors LLC now owns 13,875 shares of the company's stock worth $179,000 after purchasing an additional 3,424 shares in the last quarter. Marshall Wace LLP acquired a new position in shares of Surrozen during the fourth quarter worth about $247,000. Finally, Geode Capital Management LLC lifted its stake in shares of Surrozen by 22.6% during the second quarter. Geode Capital Management LLC now owns 30,963 shares of the company's stock worth $277,000 after purchasing an additional 5,702 shares in the last quarter. Institutional investors and hedge funds own 66.57% of the company's stock.

About Surrozen

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.